亚洲知识产权资讯网为知识产权业界提供一个一站式网上交易平台,协助业界发掘知识产权贸易商机,并与环球知识产权业界建立联系。无论你是知识产权拥有者正在出售您的知识产权,或是制造商需要购买技术以提高操作效能,又或是知识产权配套服务供应商,你将会从本网站发掘到有用的知识产权贸易资讯。

Pharmacological Screen to Identify Compounds That Facilitate NO signaling in Muscle With Deficient nNOS Localization and/or Activity

详细技术说明
Technology DescriptionResearchers have discovered a newoption for treating muscular dystrophy and other diseases associated withmuscle wasting symptoms. This option consists of the administration ofsildenafil (or another inhibitor of phosphodiesterase 5A) in affected patients priorto exercise or similar activity. The effects of this treatment areattributed to the known mechanism of action for these agents, which is theprevention of cGMP degradation. cGMP is a key messenger for initiatingvasodilation and thus increasing blood flow. When this treatment is instituted,the cGMP persists longer in smooth muscle cells and the resulting vasodilationalso persists for a greater period of time. This increase in blood flow toactive muscles slows their rate of fatigue and limits the activity-inducedmuscle tissue damage associated with myopathic conditions.Advantages Novel mechanism of action. Phosphodiesterase inhibitors work via the preservation of cGMP in blood vessels, which initiates vasodilation. It is believed that the absence of vasodilation and the resulting lack of increased blood flow play a key role in rapid muscle fatigue and muscle cell breakdown.Well-established safety profile. Sildenafil and other phosphodiesterase inhibitors have been used clinically for many years and have shown themselves to be safe for long-term use.
*Abstract
Background

There are a variety of diseases thatcause muscle weakness and muscle tissue breakdown (myopathy). The most notableof these diseases are the muscular dystrophies, but can also include suchdiverse conditions as HIV infection cancer, and aging. The symptoms ofmyopathy have a variety of causes, but all result in various levels ofdebilitation to the patient. A treatment that could slow or prevent theprogression of muscle weakness from various causes would have significant valueto patients.

*Licensing
Email: uirf-marketing@uiowa.eduPhone: (319) 335-4546
国家/地区
美国

欲了解更多信息,请点击 这里
移动设备